Provided by Tiger Trade Technology Pte. Ltd.

Alto Neuroscience Inc

25.37
-1.1400-4.30%
Post-market: 25.370.00000.00%19:30 EST
Volume:522.54K
Turnover:13.26M
Market Cap:1.02B
PE:-10.73
High:26.48
Open:25.76
Low:24.40
Close:26.51
52wk High:37.48
52wk Low:12.51
Shares:40.11M
Float Shares:30.46M
Volume Ratio:0.76
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3648
EPS(LYR):-2.1918
ROE:-46.65%
ROA:-26.54%
PB:3.43
PE(LYR):-11.57

Loading ...

Alto Neuroscience COO Michael Conick Hanley Jr. Reports Sale of $2.07 Million in Common Shares

Reuters
·
Nov 19

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcon (ALC), InMode (INMD) and Alto Neuroscience, Inc. (ANRO)

TIPRANKS
·
Nov 12

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Humacyte (HUMA) and BridgeBio Oncology Therapeutics (BBOT)

TIPRANKS
·
Nov 12

Alto Neuroscience Price Target Maintained with a $37.00/Share by BTIG

Dow Jones
·
Nov 12

Alto Neuroscience Presents ALTO-207 Development Plans for Treatment-Resistant Depression

Reuters
·
Nov 11

Alto Neuroscience Q3 EPS $(0.54) Beats $(0.67) Estimate

Benzinga Earnings
·
Nov 11

Alto Neuroscience Q3 Net Loss Widens 77% to $25.12 Million

Reuters
·
Nov 11

Press Release: Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Nov 11

Alto Neuroscience Grants New Employee Option to Buy 50,000 Shares

Reuters
·
Nov 04

Alto Neuroscience to Participate in Stifel and Jefferies Healthcare Conferences

Reuters
·
Nov 03

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

THOMSON REUTERS
·
Nov 03

Alto Neuroscience price target raised to $60 from $55 at H.C. Wainwright

TIPRANKS
·
Oct 19

HC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy Rating

MT Newswires Live
·
Oct 19

Alto Neuroscience President, CFO Nicholas Conrad Smith Disposes of Shares Worth $3,547,660.32

Reuters
·
Oct 02

Alto Neuroscience (ANRO) Defendants Move to Dismiss Third Amended Securities Complaint Over Phase 2b Trial Disclosures

TIPRANKS
·
Sep 23

Alto Neuroscience, Inc. (ANRO) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Alto Neuroscience to Present at H.C. Wainwright Global Healthcare Conference

Reuters
·
Sep 09

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

THOMSON REUTERS
·
Aug 28

Alto Neuroscience Lawsuit Dismissed for Now, With Investors Given Chance to Amend Claims

TIPRANKS
·
Aug 22

Alto Neuroscience Price Target Raised to $55.00/Share from $50.00 by HC Wainwright & Co.

Dow Jones
·
Aug 18